Clinical Trials on Ehlers-Danlos Syndrome, Type IV

Total 4947 results

BioMed Valley Discoveries, Inc

Completed

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Celgene

Terminated

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Hospices Civils de Lyon

Unknown

Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (GREFFE)

Myelodysplastic Syndromes | Myeloid Leukemia

France
Medical University of South Carolina

Terminated

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Leukemia

United States
Johann Wolfgang Goethe University Hospital

Unknown

Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) (PANOBEST)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Novartis Pharmaceuticals

Completed

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Onconova Therapeutics, Inc.

Completed

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia

United States
Dr. Avichai Shimoni MD

Completed

Treosulfan-based Conditioning for Transplantation in AML/MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Israel
BioMAS Ltd

Suspended

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Israel
Medical Research Council

Completed

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia

Myelodysplastic Syndromes | Leukemia

United Kingdom
Chimeric Therapies

Completed

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease

United States
Weill Medical College of Cornell University

Completed

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Eisai Inc.

Completed

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Completed

A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Samsung Medical Center
Jin Yang Pharmaceutical

Suspended

L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Korea, Republic of
Assistance Publique Hopitaux De Marseille

Unknown

Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

Myelodysplastic Syndromes | Myeloid Leukemia

France
Iowa State University
USA Dry Pea & Lentil Council

Completed

Metabolic Effects of Pulse Consumption on Biomarkers in Adults With Type 2 Diabetes or Met Syn (PGRIV)

Metabolic Syndrome | Type2 Diabetes Mellitus

United States
Eisai Inc.

Terminated

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Unresectable Stage III Melanoma | Wild Type BRAF Stage IV Melanoma

United States
Hospices Civils de Lyon

Not yet recruiting

Role of BMP Pathway in MDS Progression (BMP-MDS)

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

France
GluBio Therapeutics Inc.

Recruiting

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
GeneScience Pharmaceuticals Co., Ltd.
Ruijin Hospital; Shanghai Tong Ren Hospital; First Affiliated Hospital of Zhejiang...

Recruiting

Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

China
Curis, Inc.

Recruiting

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Germany, United States, Spain, Israel, Czechia, Poland, France, Italy
Edgewood Oncology Inc.

Recruiting

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Celyad Oncology SA

Recruiting

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Belgium, United States
Institut Paoli-Calmettes

Recruiting

COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (COHABILIT)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
National Cancer Institute (NCI)

Recruiting

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

Neoplasms | Myelodysplastic Syndromes | Lymphomas

United States
Celgene

Terminated

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, France, Canada, Norway, Spain, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, France, Australia, Canada, Italy, Norway, Spain, Sweden, United Kingdom
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Switzerland, France
Celgene

Completed

A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan
Technische Universität Dresden

Completed

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) (RELAZA2)

Myelodysplastic Syndrome | Acute Myelocytic Leukemia

Germany
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Leukemia | Myelodysplastic Syndrome

United States
University of Chicago

Terminated

The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
University of Campinas, Brazil

Unknown

Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Brazil
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)

Leukemia | Myelodysplastic Syndrome

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Celgene

Completed

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Leukemia, Myelomonocytic, Juvenile | Myelodysplastic Syndrome

Spain, Germany, Italy, United Kingdom, Belgium, France, Denmark, Netherlands, Sweden, Switzerland, Austria, Czechia, Ireland
Dana-Farber Cancer Institute
Eli Lilly and Company

Terminated

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
St. Jude Children's Research Hospital

Terminated

Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
GWT-TUD GmbH

Terminated

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY (SAMBA)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

France, Germany
M.D. Anderson Cancer Center
Centocor, Inc.

Completed

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Nantes University Hospital

Completed

VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome (VIDAZA-DLI)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease
Genzyme, a Sanofi Company
AnorMED

Withdrawn

AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia
National University Hospital, Singapore
Singapore General Hospital

Unknown

T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Singapore
Riverside Haematology Group

Unknown

Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Myelodysplastic Syndromes | Leukemia

United Kingdom
M.D. Anderson Cancer Center
Sanofi

Terminated

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia

United States

3

Subscribe